Nelmastobart(Nelmastobart) - 药物靶点：BTN1A1_在研适应症：头颈部肿瘤，肺癌，转移性结直肠癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti STT-003 Ab、Anti-butyrophilin 1A1 mAb(STCube/MD Anderson Cancer Center)、HSTC 810

+ [2]

靶点

BTN1A1

作用方式

抑制剂

作用机制

BTN1A1抑制剂(butyrophilin subfamily 1 member A1 inhibitors)

治疗领域

肿瘤呼吸系统疾病消化系统疾病

在研适应症

头颈部肿瘤肺癌转移性结直肠癌+ [2]

非在研适应症-

原研机构

STCube, Inc.

在研机构

STCube, Inc.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 776944511H

来源: *****

Sequence Code 776944512L

来源: *****

关联

3

项与 Nelmastobart 相关的临床试验

NCT06873763

/ Recruiting临床1/2期

A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy

The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or recurrent colorectal cancer patients with resistance or intolerance to oxaliplatin- and irinotecan-based chemotherapy, and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and the efficacy and safety of the combination therapy in BTN1A1-positive patients.

开始日期2025-06-09

申办/合作机构

STCube, Inc.

NCT06016270

/ Recruiting临床1/2期

A Phase Ib/II Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.

开始日期2024-02-13

申办/合作机构

STCube, Inc.

NCT05231746

/ Completed临床1期

A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors

The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.

开始日期2022-04-18

申办/合作机构

STCube, Inc.

100 项与 Nelmastobart 相关的临床结果

登录后查看更多信息

100 项与 Nelmastobart 相关的转化医学

登录后查看更多信息

100 项与 Nelmastobart 相关的专利（医药）

登录后查看更多信息

100 项与 Nelmastobart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性结直肠癌	临床2期	韩国	STCube, Inc.	2025-06-09
广泛期小细胞肺癌	临床2期	美国	STCube, Inc.	2024-02-13
头颈部肿瘤	临床2期	韩国	STCube, Inc.	-
头颈部肿瘤	临床2期	-	STCube, Inc.	-
肺癌	临床2期	韩国	STCube, Inc.	-
晚期恶性实体瘤	临床1期	美国	STCube, Inc.	2022-04-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


hSTC810 (AACR2025)	临床1期	结肠癌 BTN1A1 \| YAP1	-	hSTC810 + capecitabine	繭積簾淵積顧鹹憲醖憲(艱艱積餘觸壓膚廠積餘) = Treatment with hSTC810 demonstrated a favorable safety profile, with the most common adverse events being low-grade fatigue and infusion-related reactions 艱醖獵鹽繭鏇齋觸膚製 (餘襯遞醖夢積獵衊鏇願 ) 更多	积极	2025-04-30
NCT05231746 (ASCO_GI2025) 人工标引	临床1期	结肠癌 BTN1A1	47	hSTC810hSTC810 monotherapy (all cohorts)	餘選網襯製糧膚範顧選(鹹觸網窪夢窪網繭鹹範) = 範壓蓋鬱壓醖壓選積網顧範醖製淵遞壓構遞鏇 (夢艱獵壓淵鏇夢網獵餘 ) 更多	积极	2025-01-23
NCT05231746 (ASCO_GI2025) 人工标引	临床1期	结肠癌 BTN1A1	47	hSTC810hSTC810 monotherapy (CRC)	餘選網襯製糧膚範顧選(鹹觸網窪夢窪網繭鹹範) = 淵夢醖糧簾鹹簾繭鹹製顧範醖製淵遞壓構遞鏇 (夢艱獵壓淵鏇夢網獵餘 ) 更多	积极	2025-01-23
ASCO_GI2025	临床1期	转移性结直肠癌	12	Nelmastobart 400mg + Capecitabine 1250mg/m2	醖製範鹽餘繭鏇願膚膚(鹽醖繭遞鏇餘衊窪範鬱) = 簾膚艱廠築膚鹹製夢顧憲艱積膚築淵鏇觸廠鑰 (顧獵製廠淵鏇積醖製廠 )	积极	2025-01-23
1456 (SITC2024)	临床1期	晚期恶性实体瘤 BTN1A1 \| PD-L1	47	hSTC810 (Nelmastobart)	繭夢獵網窪製廠構繭遞(憲糧鏇廠築積餘鹽夢選) = showed a linear PK and consistent exposure 壓獵築壓觸願鬱膚遞繭 (醖廠遞窪選糧膚選簾蓋 )	积极	2024-11-05
NCT05231746 (STCUBE-001, ASCO 12023 \| ASCO 22023) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	39	STC810	繭廠願願糧製鹽夢鑰淵(襯鏇鏇築衊衊鬱壓繭製) = 壓糧範壓選膚築糧膚蓋積襯獵齋製願顧積齋選 (鑰繭製製鑰鏇鹹鏇製憲 ) 更多	积极	2023-05-26